Biogen continues with new data in adults and infants

CAMBRIDGE, Mass., April 12, 2019 (GLOBE NEWSWIRE)Biogen (Nasdaq: BIIB) today announced it will present new data illustrating the rapidly progressive nature of spinal muscular atrophy (SMA) in adults, adolescents and older children at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida (April 13-17, 2019). Other Biogen presentations will highlight the benefits of pre-symptomatic treatment with data from the NURTURE study, part of the SPINRAZA® (nusinersen) global clinical trial program, and findings on the role of neurofilament as a potential biomarker for predicting motor function in SMA.

Publicerat av



Att acceptera vad som händer och låt trollen i ljuset, kanske du borde att tro mer på dig själv Liz Photopage Instagram

En kommentar till “Biogen continues with new data in adults and infants”

  1. “The data show that, if left untreated, people with all types of SMA continue to experience increased health challenges, and that slowing the progression of the disease, even for those with less severe forms, is critical to their ongoing health,” said Wildon Farwell, M.D., senior medical director, clinical development at Biogen. “With more than 6,600 individuals treated with SPINRAZA across the post-marketing setting, expanded access program and clinical trials and over six years of clinical data, we continue to expand our in-depth knowledge of the disease and to gain real-world experience on long-term safety and efficacy. We plan to continue advancing research to help shape care for individuals with SMA today and in the future.”

    Read more about the new presentations on SMA and SPINRAZA

    #Behandlung mit Spinraza bei Erwachsenen

Lämna ett svar

E-postadressen publiceras inte. Obligatoriska fält är märkta *